不同品系小鼠对抗生素的耐受度不同
  • 不同品系小鼠对抗生素的耐受度不同;
  • 相比于C57BL/6,BALB/c小鼠不能耐受目前发表的氨苄西林(A)和链霉素(S)浓度,但可以耐受1/10的浓度,两个品系均能耐受发表的粘菌素(C)浓度;
  • 将三种抗生素混合,C57BL/6的耐受度较好,而BALB/c仅能耐受1/10的浓度,但这种浓度不足以删除肠道菌群;
  • DBA/2品系小鼠同样对抗生素的耐受度较差;
  • 目前的抗生素方案是1mg/ml A+1mg/ml C+5mg/ml S,能有效清除肠道菌群,但仅有C57BL/6可耐受。
主编推荐语
章台柳
为什么肠道微生物组对检查点抑制剂癌症治疗的成功至关重要,这是一个尚未解答的问题,目前相关的研究进展推进得较为缓慢。Journal for ImmunoTherapy of Cancer近期发表的观点性文章,发现目前使用的抗生素混合物口感较苦,仅能被C57BL/6小鼠耐受,不被其他常见小鼠品系(即BALB/c和DBA/2)耐受(导致小鼠饮水较少,体重减轻)。这提醒研究人员在计划研究肠道微生物群的癌症实验时,必须考虑这一重要的生物学限制,以防止实验动物不必要的脱水。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!

Gut microbiome-depleting antibiotic regimens are not tolerated by all mouse strains: learn from (our) bitter experience

并非所有小鼠品系都能耐受肠道微生物组删除的抗生素方案:从我们的痛苦经历中吸取教训

10.1136/jitc-2022-005575

2022-11-02, News & Views

Abstract & Authors:展开

Abstract:收起
Why the gut microbiome is critical for the success of checkpoint inhibitor cancer therapy is a question that remains unanswered, but progress has slowed. We argue that this lack of advancement is due to an unappreciated biological detail. Here, we show that the antibiotic cocktail used in seminal publications—all of which have used the C57BL/6 mouse strain—are bitter and not tolerated by other common mouse strains (ie, BALB/c and DBA/2). We write to alert readers of this important biological limitation that must be considered when planning cancer experiments investigating the gut microbiota, to prevent the unnecessary dehydration of experimental animals, and to save our colleagues valuable experimental time and resources.

First Authors:
Andrew A Almonte

Correspondence Authors:
Aude M Fahrer

All Authors:
Andrew A Almonte,George Cavic,Teresa Neeman,Anselm Enders,Aude M Fahrer

评论